Cardiac Dysrhythmias

  • Neil Christopher
  • Wan-Tsu W. ChangEmail author


Cardiac dysrhythmias encountered in the emergency and critical care setting are often life-threatening situations, requiring emergent diagnosis as well as therapeutic intervention. In some cases, intervention may be required to stabilize the patient even prior to establishing a firm diagnosis. Thus, a structured approach to dysrhythmias is essential to ensure that key diagnostics and appropriate treatment modalities are not overlooked. In this chapter, we review the most common dysrhythmias encountered in the emergency department and their management.


Dysrhythmias Bradydysrhythmias Tachydysrhythmias Pacing Cardioversion 


  1. 1.
    Brady WJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation. 1999;41(1):47–55.PubMedGoogle Scholar
  2. 2.
    Bernheim A, et al. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. Transplantation. 2004;77(8):1181–5.PubMedGoogle Scholar
  3. 3.
    The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.3: Management of symptomatic bradycardia and tachycardia. Circulation. 2005;112(24_supplement):IV-67-IV-77.Google Scholar
  4. 4.
    Momeni M, et al. Anaphylactic shock in a beta-blocked child: usefulness of isoproterenol. Paediatr Anaesth. 2007;17(9):897–9.PubMedGoogle Scholar
  5. 5.
    Truitt CA, et al. Outcomes of unintentional beta-blocker or calcium channel blocker overdoses: a retrospective review of poison center data. J Med Toxicol. 2012;8(2):135–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Love JN, et al. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest. 1998;114(1):323–6.PubMedGoogle Scholar
  7. 7.
    Ma G, et al. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med. 2001;20(2):145–52.PubMedGoogle Scholar
  8. 8.
    Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am Coll Cardiol. 2001;37(1):153–6.PubMedGoogle Scholar
  9. 9.
    Morelli A, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683–91.PubMedGoogle Scholar
  10. 10.
    Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol. 1980;314:445–56.Google Scholar
  11. 11.
    Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature. 1981;294(5841):582–4.PubMedGoogle Scholar
  12. 12.
    Wellens HJ. 25 years of insights into the mechanisms of supraventricular arrhythmias. Heart Rhythm. 2004;1(5 Suppl):19C–25C.PubMedGoogle Scholar
  13. 13.
    Gomes JA, Mehta D, Langan MN. Sinus node reentrant tachycardia. Pacing Clin Electrophysiol. 1995;18(5 Pt 1):1045–57.PubMedGoogle Scholar
  14. 14.
    Goyal R, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J. 1996;132(4):765–7.PubMedGoogle Scholar
  15. 15.
    Kumar UN, Rao RK, Scheinman MM. The 12-lead electrocardiogram in supraventricular tachycardia. Cardiol Clin. 2006;24(3):427–37, ix.PubMedGoogle Scholar
  16. 16.
    Delacretaz E. Supraventricular tachycardia. N Engl J Med. 2006;354(10):1039–51.PubMedGoogle Scholar
  17. 17.
    Rodriguez LM, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol. 1992;70(13):1213–5.PubMedGoogle Scholar
  18. 18.
    Lau EW, et al. Electrocardiographic criteria for diagnosis of irregular broad complex tachycardia with a high sensitivity for preexcited atrial fibrillation. Pacing Clin Electrophysiol. 2000;23(12):2040–5.PubMedGoogle Scholar
  19. 19.
    Fengler BT, et al. Atrial fibrillation in the Wolff-Parkinson-white syndrome: ECG recognition and treatment in the ED. Am J Emerg Med. 2007;25:576–83.PubMedGoogle Scholar
  20. 20.
    Steinbeck G, Hoffmann E. 'True' atrial tachycardia. Eur Heart J. 1998;19(Suppl E):E10-2, E48.Google Scholar
  21. 21.
    Ko JK, et al. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol. 1992;69(12):1028–32.PubMedGoogle Scholar
  22. 22.
    Gillette PC. The mechanisms of supraventricular tachycardia in children. Circulation. 1976;54(1):133–9.PubMedGoogle Scholar
  23. 23.
    Wu MH, et al. Radiofrequency catheter ablation of tachycardia in children with and without congenital heart disease: indications and limitations. Int J Cardiol. 2000;72(3):221–7.PubMedGoogle Scholar
  24. 24.
    Garson A, Gillette PC. Electrophysiologic studies of supraventricular tachycardia in children. I. Clinical-electrophysiologic correlations. Am Heart J. 1981;102(2):233–50.PubMedGoogle Scholar
  25. 25.
    Blomstrom-Lundqvist C, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for the management of patients with Supraventricular Arrhythmias). Circulation. 2003;108(15):1871–909.PubMedGoogle Scholar
  26. 26.
    McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998;113(1):203–9.PubMedGoogle Scholar
  27. 27.
    Ruder MA, et al. Clinical and electrophysiologic characterization of automatic junctional tachycardia in adults. Circulation. 1986;73(5):930–7.PubMedGoogle Scholar
  28. 28.
    Lee KL, et al. Effect of adenosine and verapamil in catecholamine-induced accelerated atrioventricular junctional rhythm: insights into the underlying mechanism. Pacing Clin Electrophysiol. 1999;22(6 Pt 1):866–70.PubMedGoogle Scholar
  29. 29.
    Castellanos A, Sung RJ, Myerburg RJ. His bundle electrocardiography in digitalis-induced "atrioventricular junctional" Wenckebach periods with irregular H-H intervals. Am J Cardiol. 1979;43(3):653–6.PubMedGoogle Scholar
  30. 30.
    Accardi AJ, Miller R, Holmes JF. Enhanced diagnosis of narrow complex tachycardias with increased electrocardiograph speed. J Emerg Med. 2002;22(2):123–6.PubMedGoogle Scholar
  31. 31.
    Lim SH, et al. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med. 1998;31(1):30–5.PubMedGoogle Scholar
  32. 32.
    Mehta D, et al. Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet. 1988;1(8596):1181–5.PubMedGoogle Scholar
  33. 33.
    Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation. 2003;107(8):1096–9.PubMedGoogle Scholar
  34. 34.
    Dimarco JP, Miles W, Akhtar M. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990;113(2):104–10.PubMedGoogle Scholar
  35. 35.
    Holdgate A, Ching N, Angonese L. Variability in agreement between physicians and nurses when measuring the Glasgow Coma Scale in the emergency department limits its clinical usefulness. Emerg Med Australas. 2006;18(4):379–84.PubMedGoogle Scholar
  36. 36.
    Mallet ML. Proarrhythmic effects of adenosine: a review of the literature. Emerg Med J. 2004;21(4):408–10.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation. 2002;52(2):167–74.PubMedGoogle Scholar
  38. 38.
    Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother. 2000;34(5):622–9.PubMedGoogle Scholar
  39. 39.
    Tijunelis MA, Herbert ME. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-white syndrome in the emergency department. CJEM. 2005;7(4):262–5.PubMedGoogle Scholar
  40. 40.
    Fuster V, et al. ACC/AHA/ESC guidelines for the Management of Patients with Atrial Fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118–50.PubMedGoogle Scholar
  41. 41.
    European Heart Rhythm Association, E.A.f.C.-T.S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.Google Scholar
  42. 42.
    Naccarelli GV, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–9.PubMedGoogle Scholar
  43. 43.
    Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol. 1997;30(6):1506–11.PubMedGoogle Scholar
  44. 44.
    Ghali WA, et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med. 2005;118(2):101–7.PubMedGoogle Scholar
  45. 45.
    Coyne KS, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348–56.PubMedGoogle Scholar
  46. 46.
    Kannel WB, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306(17):1018–22.PubMedGoogle Scholar
  47. 47.
    Benjamin EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.PubMedGoogle Scholar
  48. 48.
    Pollock GF. Atrial fibrillation in the ED: cardioversion, rate control, anticoagulation, and more. Emergency Medicine Practice. 2002;4(8):1–28.Google Scholar
  49. 49.
    Badheka AO, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010;123(7):646–51.PubMedGoogle Scholar
  50. 50.
    Friedman HZ, et al. Acute complications associated with new-onset atrial fibrillation. Am J Cardiol. 1991;67(5):437–9.PubMedGoogle Scholar
  51. 51.
    Zimetbaum PJ, et al. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol. 2000;36(4):1223–7.PubMedGoogle Scholar
  52. 52.
    Laurent G, et al. Atrial fibrillation during myocardial infarction with and without ST segment elevation. Arch Mal Coeur Vaiss. 2005;98(6):608–14.PubMedGoogle Scholar
  53. 53.
    Meshkat N, et al. Troponin utilization in patients presenting with atrial fibrillation/flutter to the emergency department: retrospective chart review. Int J Emerg Med. 2011;4(1):25.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J. 2006;27(16):1979–2030.PubMedGoogle Scholar
  55. 55.
    Allessie MA, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103(5):769–77.PubMedGoogle Scholar
  56. 56.
    Ruskin J, et al. Pressure-flow studies in man: effect of atrial systole on left ventricular function. J Clin Invest. 1970;49(3):472–8.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Rahimtoola SH, et al. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med. 1975;59(5):686–94.PubMedGoogle Scholar
  58. 58.
    Grogan M, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69(19):1570–3.PubMedGoogle Scholar
  59. 59.
    Iga K, et al. Reversible left ventricular dysfunction secondary to rapid atrial fibrillation. Int J Cardiol. 1993;41(1):59–64.PubMedGoogle Scholar
  60. 60.
    Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med. 2004;164(15):1675–8.PubMedGoogle Scholar
  61. 61.
    Weekes AJ, Zapata RJ, Napolitano A. Symptomatic hypotension: ED stabilization and the emerging role of sonography. EM Pract. 2007;9:1–28.Google Scholar
  62. 62.
    Perera P, et al. The RUSH exam: rapid ultrasound in SHock in the evaluation of the critically ill. Emerg Med Clin North Am. 2010;28(1):29–56, vii.PubMedGoogle Scholar
  63. 63.
    Atkinson PR, et al. Abdominal and Cardiac Evaluation with Sonography in Shock (ACES): an approach by emergency physicians for the use of ultrasound in patients with undifferentiated hypotension. Emerg Med J. 2009;26(2):87–91.PubMedGoogle Scholar
  64. 64.
    Dipti A, et al. Role of inferior vena cava diameter in assessment of volume status: a meta-analysis. Am J Emerg Med. 2012;30(8):1414–1419.e1.PubMedGoogle Scholar
  65. 65.
    Barbier C, et al. Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients. Intensive Care Med. 2004;30(9):1740–6.PubMedGoogle Scholar
  66. 66.
    Brodsky MA, et al. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol. 1989;63(15):1065–8.PubMedGoogle Scholar
  67. 67.
    Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation. 1998;98(5):479–86.PubMedGoogle Scholar
  68. 68.
    Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129(1):71–5.PubMedGoogle Scholar
  69. 69.
    Manning WJ, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328(11):750–5.PubMedGoogle Scholar
  70. 70.
    Black IW, et al. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J. 1993;126(2):375–81.PubMedGoogle Scholar
  71. 71.
    Corrado G, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest. 1999;115(1):140–3.PubMedGoogle Scholar
  72. 72.
    Klein AL, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411–20.PubMedGoogle Scholar
  73. 73.
    Klein AL, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of cardioversion using transesophageal echocardiography. Ann Intern Med. 1997;126(3):200–9.PubMedGoogle Scholar
  74. 74.
    Neumar RW, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):S729–67.PubMedGoogle Scholar
  75. 75.
    Page RL, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002;39(12):1956–63.PubMedGoogle Scholar
  76. 76.
    Cohen TJ, et al. Active compression cardioversion for refractory atrial fibrillation. Am J Cardiol. 1997;80(3):354–5.PubMedGoogle Scholar
  77. 77.
    Weingart S. The crashing atrial fibrillation patient. In: Weingart S, editor. The EMCrit blog; 2012. Scholar
  78. 78.
    Allen R. Preventing hypotension effect of calcium channel blockers. Am Fam Physician. 2003;67(5):940; author reply 940–1.Google Scholar
  79. 79.
    Lipman J, et al. Intravenous calcium chloride as an antidote to verapamil-induced hypotension. Intensive Care Med. 1982;8(1):55–7.PubMedGoogle Scholar
  80. 80.
    Midtbo K, Hals O. Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion? Pharmacol Toxicol. 1987;60(5):330–2.PubMedGoogle Scholar
  81. 81.
    Weiss AT, et al. The use of calcium with verapamil in the management of supraventricular tachyarrhythmias. Int J Cardiol. 1983;4(3):275–84.PubMedGoogle Scholar
  82. 82.
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789–94.PubMedGoogle Scholar
  83. 83.
    Wyse DG, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.PubMedGoogle Scholar
  84. 84.
    Van Gelder IC, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40.PubMedGoogle Scholar
  85. 85.
    Carlsson J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–6.PubMedGoogle Scholar
  86. 86.
    Opolski G, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest. 2004;126(2):476–86.PubMedGoogle Scholar
  87. 87.
    Roy D, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–77.PubMedGoogle Scholar
  88. 88.
    Ogawa S, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J. 2009;73(2):242–8.PubMedGoogle Scholar
  89. 89.
    Stiell IG, et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010;12(3):181–91.PubMedGoogle Scholar
  90. 90.
    Scheuermeyer FX, Grafstein E, Stenstrom R. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med. 2010;17(4):408–15.Google Scholar
  91. 91.
    Cristoni L, et al. Cardioversion of acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical cardioversion with simple antiarrhythmic treatment. Emerg Med J. 2011;28(11):932–7.PubMedGoogle Scholar
  92. 92.
    Doyle B, Reeves M. Wait and see” approach to the emergency department cardioversion of acute atrial fibrillation. Emerg Med Int. 2011;2011:545023.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Stiell IG, Macle L, C.C.S.A.F.G. Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can J Cardiol. 2011;27(1):38–46.PubMedGoogle Scholar
  94. 94.
    Bellone A, et al. Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial. Emerg Med J. 2012;29(3):188–91.PubMedGoogle Scholar
  95. 95.
    Abarbanell NR, et al. Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. Am J Emerg Med. 2001;19(1):6–9.PubMedGoogle Scholar
  96. 96.
    Camm AJ, Camm CF, Savelieva I. Medical treatment of atrial fibrillation. J Cardiovasc Med (Hagerstown). 2012;13(2):97–107.Google Scholar
  97. 97.
    Blecher GE, et al. Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates. CJEM. 2012;14(3):169–77.PubMedGoogle Scholar
  98. 98.
    Scheuermeyer FX, et al. Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause. Ann Emerg Med. 2012;60(6):755–765.e2.PubMedGoogle Scholar
  99. 99.
    Phillips BG, et al. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997;17(6):1238–45.PubMedGoogle Scholar
  100. 100.
    Demircan C, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005;22(6):411–4.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Lip GYH, Tse H-F. Management of atrial fibrillation. Lancet. 2007;370(9587):604–18.PubMedGoogle Scholar
  102. 102.
    Siu C-W, et al. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med. 2009;37(7):2174–9; quiz 2180.PubMedGoogle Scholar
  103. 103.
    Jacob S, et al. Pharmacotherapy of atrial fibrillation: a pathophysiological perspective and review. Am J Ther. 2011;18(3):241–60.PubMedGoogle Scholar
  104. 104.
    Cheng JWM, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8(5):419–27.PubMedGoogle Scholar
  105. 105.
    Lee G. A review of the literature on atrial fibrillation: rate reversion or control? J Clin Nurs. 2007;16(1):77–83.PubMedGoogle Scholar
  106. 106.
    Hou ZY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16(4):521–8.PubMedGoogle Scholar
  107. 107.
    Lie KI, van Gelder IC. Therapy of recent onset atrial fibrillation and flutter in haemodynamically compromised patients: chemical conversion or control of the ventricular rate? Eur Heart J. 1995;16(4):433–4.PubMedGoogle Scholar
  108. 108.
    Brodsky MA, et al. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 1994;73(16):1227–9.PubMedGoogle Scholar
  109. 109.
    Chiladakis JA, et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol. 2001;79(2–3):287–91.PubMedGoogle Scholar
  110. 110.
    Chu K, et al. Magnesium sulfate versus placebo for paroxysmal atrial fibrillation: a randomized clinical trial. Acad Emerg Med. 2009;16(4):295–300.PubMedGoogle Scholar
  111. 111.
    Gullestad L, et al. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 1993;16(5):429–34.PubMedGoogle Scholar
  112. 112.
    Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med. 1994;24(1):61–4.PubMedGoogle Scholar
  113. 113.
    Moran JL, et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 1995;23(11):1816–24.PubMedGoogle Scholar
  114. 114.
    Stiell IG, et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med. 2007;14(12):1158–64.PubMedGoogle Scholar
  115. 115.
    Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82(12):1545–7, A8.PubMedGoogle Scholar
  116. 116.
    Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol. 1996;78(4):435–9.PubMedGoogle Scholar
  117. 117.
    Weigner MJ, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615–20.PubMedGoogle Scholar
  118. 118.
    Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29(6):1083–91.PubMedGoogle Scholar
  119. 119.
    Hart RG, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501.PubMedGoogle Scholar
  120. 120.
    Investigators A, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78.Google Scholar
  121. 121.
    Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.Google Scholar
  122. 122.
    Domanovits H, et al. Sustained ventricular tachycardia in the emergency department. Resuscitation. 1999;42(1):19–25.PubMedGoogle Scholar
  123. 123.
    Herbert ME, et al. Failure to agree on the electrocardiographic diagnosis of ventricular tachycardia. Ann Emerg Med. 1996;27(1):35–8.PubMedGoogle Scholar
  124. 124.
    Akhtar M, et al. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med. 1988;109(11):905–12.PubMedGoogle Scholar
  125. 125.
    Baerman JM, et al. Differentiation of ventricular tachycardia from supraventricular tachycardia with aberration: value of the clinical history. Ann Emerg Med. 1987;16(1):40–3.PubMedGoogle Scholar
  126. 126.
    Josephson ME. Electrophysiology of ventricular tachycardia: an historical perspective. J Cardiovasc Electrophysiol. 2003;14(10):1134–48.PubMedGoogle Scholar
  127. 127.
    Stevenson WG. Catheter ablation of monomorphic ventricular tachycardia. Curr Opin Cardiol. 2005;20(1):42–7.PubMedGoogle Scholar
  128. 128.
    Koppel C, et al. Clinical course and outcome in class IC antiarrhythmic overdose. Clin Toxicol. 1990;28(4):433–44.Google Scholar
  129. 129.
    Al-Khatib SM, et al. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120–7.PubMedGoogle Scholar
  130. 130.
    Thanacoody HKR, Thomas SHL. Tricyclic antidepressant poisoning : cardiovascular toxicity. Toxicol Rev. 2005;24(3):205–14.PubMedGoogle Scholar
  131. 131.
    Bradberry SM, et al. Management of the cardiovascular complications of tricyclic antidepressant poisoning: role of sodium bicarbonate. Toxicol Rev. 2005;24(3):195–204.PubMedGoogle Scholar
  132. 132.
    Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995;26(2):195–201.PubMedGoogle Scholar
  133. 133.
    Dittrich KL, Walls RM. Hyperkalemia: ECG manifestations and clinical considerations. J Emerg Med. 1986;4(6):449–55.PubMedGoogle Scholar
  134. 134.
    Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18(6):721–9.PubMedGoogle Scholar
  135. 135.
    Fisch C. Relation of electrolyte disturbances to cardiac arrhythmias. Circulation. 1973;47(2):408–19.PubMedGoogle Scholar
  136. 136.
    Danaberg J. Electrolyte abnormalities affecting the heart. In: Schwartz GR, editor. Principles and practice of emergency medicine. Baltimore: Williams & Wilkins; 1999. p. 425–7.Google Scholar
  137. 137.
    Sobel RM, et al. Pacemaker-mediated tachycardia: management by pacemaker interrogation/ reprogramming in the ED. Am J Emerg Med. 2002;20:336–9.PubMedGoogle Scholar
  138. 138.
    Love CJ. Pacemaker troubleshooting and follow-up. In: KA KGE, Lau C, et al., editors. Clinical cardiac pacing, defibrillation, and resynchronization therapy. Philadelphia: Saunders; 2007. p. 1047–53.Google Scholar
  139. 139.
    Griffin J, Smithline H, Cook J. Runaway pacemaker: a case report and review. J Emerg Med. 2000;19(2):177–81.PubMedGoogle Scholar
  140. 140.
    Makaryus AN, Patrick C, Maccaro P. A rare case of "runaway" pacemaker in a modern CPU-controlled pacemaker. Pacing Clin Electrophysiol. 2005;28(9):993–6.PubMedGoogle Scholar
  141. 141.
    Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med. 1986;104(6):766–71.PubMedGoogle Scholar
  142. 142.
    Steinman RT, et al. Wide QRS tachycardia in the conscious adult. Ventricular tachycardia is the most frequent cause. JAMA. 1989;261(7):1013–6.PubMedGoogle Scholar
  143. 143.
    Delbridge TR, Yealy DM. Wide complex tachycardia. Emerg Med Clin North Am. 1996;13:902–24.Google Scholar
  144. 144.
    Wrenn K. Management strategies in wide QRS complex tachycardia. Am J Emerg Med. 1991;9(6):592–7.PubMedGoogle Scholar
  145. 145.
    Gupta AK, Thakur RK. Wide QRS complex tachycardias. Med Clin North Am. 2001;85(2):245–66, ix.PubMedGoogle Scholar
  146. 146.
    Dongas J, et al. Value of preexisting bundle branch block in the electrocardiographic differentiation of supraventricular from ventricular origin of wide QRS tachycardia. Am J Cardiol. 1985;55(6):717–21.PubMedGoogle Scholar
  147. 147.
    Guo H, et al. Ventricular tachycardia with QRS configuration similar to that in sinus rhythm and a myocardial origin: differential diagnosis with bundle branch reentry. Europace. 2001;3(2):115–23.PubMedGoogle Scholar
  148. 148.
    Oreto G, et al. Wide complex tachycardia with atrioventricular dissociation and QRS morphology identical to that of sinus rhythm: a manifestation of bundle branch reentry. Heart. 1996;76(6):541–7.PubMedPubMedCentralGoogle Scholar
  149. 149.
    Chou TC. Electrocardiography in clinical practice: adult and pediatric. 4th ed. Philadelphia: WB Saunders Company; 1996.Google Scholar
  150. 150.
    Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with Ventricular Arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for management of patients with Ventricular Arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385–484.PubMedGoogle Scholar
  151. 151.
    Gorgels AP, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78(1):43–6.PubMedGoogle Scholar
  152. 152.
    Marill KA, et al. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med. 2006;47(3):217–24.PubMedGoogle Scholar
  153. 153.
    Ho DS, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344(8914):18–23.PubMedGoogle Scholar
  154. 154.
    Dorian P, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346(12):884–90.PubMedGoogle Scholar
  155. 155.
    Somberg JC, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90(8):853–9.PubMedGoogle Scholar
  156. 156.
    Association, A.H. AHA guidelines for cardiopulmonary resuscitation and emergency cardiovascular care management of symptomatic Bradycardia and Tachycardia. Circulation. 2005;112(Suppl I):IV–67-IV-77.Google Scholar
  157. 157.
    Tomlinson DR, Cherian P, Betts TR. Should intravenous amiodorone be utilized for haemodynamically tolerated sustained monomorphic ventricular tachycardia? J Am Coll Cardiol. 2007;49(9):19A. Suppl A.Google Scholar
  158. 158.
    Timperley J, et al. Flecainide overdose--support using an intra-aortic balloon pump. BMC Emerg Med. 2005;5:10.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Goldman MJ, Mowry JB, Kirk MA. Sodium bicarbonate to correct widened QRS in a case of flecainide overdose. J Emerg Med. 1997;15(2):183–6.PubMedGoogle Scholar
  160. 160.
    Brubacher J. Bicarbonate therapy for unstable propafenone-induced wide complex tachycardia. CJEM. 2004;6(5):349–56.PubMedGoogle Scholar
  161. 161.
    Salerno DM, et al. Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs. Am J Emerg Med. 1995;13(3):285–93.PubMedGoogle Scholar
  162. 162.
    Bauman JL, et al. Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine. Chest. 1987;92(3):573–5.PubMedGoogle Scholar
  163. 163.
    Siegers A, Board PN. Amiodarone used in successful resuscitation after near-fatal flecainide overdose. Resuscitation. 2002;53(1):105–8.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Emergency MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of Emergency MedicineUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations